the market?
Eli Lilly & Co.
NYSE: LLY
52.35
-0.01
(-0.02%)
| Today's Open | $52.47 |
|---|---|
| Previous Close | $52.36 |
| Daily Range | $51.69 - $52.72 |
| 52-Week Range | $41.41 - $58.41 |
| Market Cap | $59.0B |
| P/E Ratio | 12.56 |
| Dividend (Yield) | $1.96 (3.7%) |
| Ex-Dividend Date Dividend Pay Date |
05/14/13 06/10/13 |
| Volume | 5,087,220 |
| Average Daily Volume | 5,816,001 |
| Current FY EPS | $3.91 |
How do you think LLY
will perform against the market?
Top LLY Bull/Bear Pitches
cibient (14.8)
Submitted
May 26, 2011
5% divy, sustainable payout ratio (45% according to Yahoo! Finance), MFI stats from <a href="http://MagicDiligence.com">MagicDiligence.com</a>:<br /><br />Results for ticker 'LLY' (Eli Lilly and Compa … More
bobbyvee (< 20)
Submitted
March 7, 2009
Pharaceuticals will suffer under this administration's plan for universal care
News & Commentary
The FDA Might Pull This Drug From the Market (and Why It Doesn't Matter)
Two deaths after patients take Eli Lilly's Zyprexa Relprevv.Is a Type 1 Diabetes Cure Right Around the Corner?
Exciting new research unlocks the root cause of type 1 diabetes.Why MannKind Is Poised to Pull Back
Market-lagging returns could be written in this 2-star stock.Consumer Staples Leading Canadian Market Higher; Transition Therapeutics Jumps After Lilly Makes Mil
Consumer Staples Leading Canadian Market Higher; Transition Therapeutics Jumps After Lilly Makes Milestone PaymentEli Lilly to Take Over Development of Diabetes Drug
Eli Lilly to pay Transition Therapeutics $7 million initially for the drug being developed to treat type 2 diabetes and accompanying obesity.Sector
Healthcare
Industry
Drugs
Eli Lilly & Co. (LLY) Description
The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases. Website: http://www.lilly.com/
CEO Rating by Glassdoor
More details for Eli Lilly Jobs
Eli Lilly reviews from employees
